Surrozen, Inc. SRZN

Healthcare — Biotechnology

Insider Buys (last 12m)

Insider Buys alert about insiders buying in the last 12 month

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

	Sep '20	Dec '20	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
ROE	0.00%	0.00%	—	0.00%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
ROA	0.00%	0.00%	—	0.00%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
ROIC	0.00%	0.00%	0.00%	0.00%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Cash ROIC	0.00%	0.00%	0.00%	(447.92%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Return on Tangible Assets	0.00%	0.00%	0.00%	5,540.79%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Accounts Receivable Turnover	—	—	—	—	—	—	—	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Accounts Payable Turnover	—	—	—	—	—	—	—	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Inventory Turnover	—	—	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—	—	—	—	—	—	—	—	—	—	—
Average Days of Receivables	—	—	—	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Days of Payables	—	0.00	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Days of Inventory on Hand	—	—	—	—	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—	—	—	—	—	—	—	—	—	—	—
Tax Rate	—	—	—	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Research and Development Expense of Revenue	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Selling, General and Administrative Expense of Revenue	—	—	—	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Share Based Compensation of Revenue	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Coverage	—	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Operating CF/Net income	—	—	—	0.69	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Depreciation/Fixed assets	—	0.00	—	0.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex/Depreciation	—	—	—	(0.40)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡
Revenue per Share	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF per Share	0.00	0.00	0.00	(19.87)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex per Share	0.00	0.00	0.00	(0.33)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow per Share	0.00	0.00	0.00	(20.20)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow	—	—	—	(24.55)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capital Expenditures	—	—	—	(0.40)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Piotroski F-Score	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	—	—	—	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Capex to Sales	—	—	—	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Profit Margin	—	—	—	0.00%	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now